What are the indications, recommended dosage, contraindications, side effects, and off‑label uses of Acebrophylline 200 mg tablets combined with N‑acetylcysteine?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Acebrophylline 200 mg + N-Acetylcysteine: Clinical Information

For patients with moderate to severe COPD or chronic bronchitis with frequent exacerbations, the combination of acebrophylline 200 mg with N-acetylcysteine (particularly at 1200 mg/day) is indicated as add-on therapy to reduce exacerbations and improve mucociliary clearance.

Indications

Primary Indications

  • Chronic Obstructive Pulmonary Disease (COPD) - moderate to severe, particularly with chronic bronchitic phenotype 1, 2
  • Chronic bronchitis with viscid mucous secretions 3
  • Bronchiectasis with excessive sputum production 4
  • Asthma - moderate to severe as adjunctive therapy 5

Specific Clinical Scenarios

N-acetylcysteine is indicated for abnormal, viscid, or inspissated mucous secretions in 3:

  • Chronic emphysema with bronchitis
  • Chronic asthmatic bronchitis
  • Bronchiectasis
  • Acute bronchopulmonary disease (pneumonia, bronchitis)
  • Pulmonary complications of cystic fibrosis
  • Post-surgical pulmonary complications
  • Atelectasis due to mucous obstruction

Acebrophylline acts as an airway mucoregulator with anti-inflammatory properties, reducing mucus viscosity and improving ciliary clearance while decreasing bronchial hyperresponsiveness 6.

Dosage

Standard Regimen

  • N-acetylcysteine: 1200 mg/day (600 mg twice daily) is superior to 600 mg/day 4

    • The 1200 mg dose reduces exacerbations by 48.6%, hospitalizations by 29.9%, and sputum volume significantly more than 600 mg 4

  • Acebrophylline: 200 mg once or twice daily (specific dosing from clinical practice, as acebrophylline is typically dosed 100-200 mg twice daily)

Treatment Duration

  • Minimum 90 days for clinical benefit 5
  • Long-term maintenance therapy for patients with recurrent exacerbations 1, 2

When to Add This Combination

Add to patients already on optimal inhaled therapy (LAMA/LABA/ICS triple therapy) who continue to exacerbate 2. The 2023 Canadian Thoracic Society guidelines suggest N-acetylcysteine for high-risk COPD patients with chronic bronchitic phenotype despite triple therapy 2.

Contraindications

Absolute Contraindications

  • Known hypersensitivity to N-acetylcysteine or acebrophylline 3

Relative Contraindications/Cautions

For N-acetylcysteine 3:

  • Active peptic ulcer disease
  • Severe hepatic impairment (though used in acetaminophen overdose)

For acebrophylline (theophylline derivative):

  • Uncontrolled cardiac arrhythmias
  • Acute myocardial infarction
  • Severe hyperthyroidism
  • Active peptic ulcer
  • Seizure disorders

Drug Interactions

Critical monitoring required when combining with 3:

  • Other theophylline-containing products (risk of toxicity)
  • Medications affecting theophylline metabolism (fluoroquinolones, macrolides, cimetidine)

Side Effects

N-Acetylcysteine 3

Common:

  • Disagreeable odor (transient)
  • Stickiness on face with nebulization (wash with water)
  • Nausea, vomiting
  • Stomatitis
  • Rhinorrhea

Less Common:

  • Bronchospasm (particularly in asthmatic patients - have bronchodilator available)
  • Rash, urticaria

Acebrophylline

Common:

  • Gastrointestinal upset (nausea, dyspepsia)
  • Headache
  • Palpitations

Serious (theophylline-related):

  • Cardiac arrhythmias
  • Seizures (at toxic levels)
  • Severe gastrointestinal bleeding

Safety Profile

The combination showed favorable safety in a 90-day study with no severe adverse events reported 5.

Off-Label Uses

N-Acetylcysteine

Established off-label uses:

  • Contrast-induced nephropathy prophylaxis: 600 mg twice daily with hydration before contrast procedures 7
  • Acetaminophen overdose: Standard antidote therapy (different dosing - IV protocol) 8

Investigational:

  • Idiopathic pulmonary fibrosis: NOT recommended as monotherapy per 2015 ATS/ERS guidelines 9
  • Thrombotic thrombocytopenic purpura: Emerging evidence but insufficient data 10

Acebrophylline

Limited published data on off-label uses; primarily used within labeled respiratory indications.

Clinical Pearls

Monitoring Requirements:

  • Baseline and periodic pulmonary function tests (FEV1, FVC)
  • Quality of life assessments (CAT score for COPD, ACT for asthma)
  • Sputum characteristics and volume
  • Exacerbation frequency

Expected Outcomes 5:

  • FEV1 improvement: 1.287L to 1.484L over 90 days
  • CAT score improvement: 17.2 to 10.6 in COPD patients
  • Reduction in exacerbations and hospitalizations 4

Common Pitfall: Using N-acetylcysteine 600 mg/day instead of 1200 mg/day - the higher dose is significantly more effective for reducing exacerbations and sputum burden 4.

Practical Consideration: Color change to light purple in opened N-acetylcysteine bottles does not affect efficacy or safety 3.

References

6
Research

Acebrophylline: an airway mucoregulator and anti-inflammatory agent.

Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace, 2007

Related Questions

Can an adult with obstructive airway disease safely be prescribed Theophylline 200 mg, Salbutamol 4 mg, Ascoril LS syrup, Acebrophylline, and Acetylcysteine together, and what regimen is recommended?
What are the dosage ranges for N‑acetylcysteine (NAC) for its various clinical indications?
What is the recommended adult dosage, administration instructions, contraindications, precautions, and common adverse effects of acebrophylline?
Can N‑acetylcysteine (acetylcysteine) and acebrophylline be used together in an adult without hepatic or renal impairment, and what are the appropriate dosages, duration, and monitoring recommendations?
What are the recommended acetaminophen dosing guidelines for adults and children, and how do liver disease or concurrent acetaminophen use affect the dosing?
In a 56-year-old man without prostate cancer but with an enlarged prostate measuring 82 mL, what are the expected outcomes if he does not initiate dutasteride therapy?
What antiepileptic drugs are recommended for managing focal seizures in a patient undergoing hemodialysis?
What is the appropriate management of rectal cancer?
What is the appropriate brivaracetam dosing regimen for a patient on hemodialysis with focal seizures?
What is the appropriate praziquantel dose for a healthy 19‑year‑old patient?
What percentage of men retain erectile function after nerve-sparing surgery for benign prostatic hyperplasia (BPH)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.